#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Immune-mediated myositis Hereditary haemorrhagic telangiectasia Cognitive disorder Epilepsy with myoclonic-atonic seizures Osteosarcoma metastatic Bronchiectasis Mantle cell lymphoma refractory Squamous cell carcinoma of head and neck Thyroid cancer metastatic Barth syndrome Carcinoid tumour Breast angiosarcoma Arteriosclerosis Thalassaemia Muscular dystrophy More trials…

    Learn about Rare Diseases

    Congenital nephrogenic diabetes insipidus – Trials in Disease Gastrointestinal stromal tumour Gaucher’s disease type I – Basic Information Haemophilia – Basic Information Congenital nephrogenic diabetes insipidus – Diagnostics Soft tissue sarcoma – Treatment Undifferentiated sarcoma – Treatment Retinitis pigmentosa – Diagnostics Acute respiratory distress syndrome Basal cell naevus syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ruxolitinib ZUNIBERGENE ROCPARVOVEC Calcium Levofolinate Leucine Lacutamab Befiradol (18F) Propranolol Tecaginlimab Icatibant TRIGLYCERIDES MEDIUM CHAIN Thiamine SAROGLITAZAR HEMIMAGNESIUM Viltolarsen Betula Verrucosa Pollen Fingolimod Hydrochloride Leuprorelin Acetate RIMIDUCID GOCATAMIG Lebrikizumab Cefazolin More therapies…

    Learn about Your Condition

    Breast proliferative changes Andersen-Tawil syndrome Interstitial lung disease Lymphocyte adoptive therapy Retroperitoneal cancer Psoriatic arthropathy Renal cancer recurrent Invasive breast carcinoma Mixed-type liposarcoma Acute lymphocytic leukaemia Myelofibrosis High-grade B-cell lymphoma Pseudomyxoma peritonei Paresis Perineal injury More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut De Cancerologie De Lorraine

Institut De Cancerologie De Lorraine

6 Avenue De Bourgogne, Cs 30519, Vandoeuvre Les Nancy, 54519, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Anastrozole
    • Goserelin
    • Letrozole
    Austria Belgium France Germany Hungary Ireland +4

  • Study on Preserving the Voice Box in Patients with Advanced Laryngeal or Hypopharyngeal Cancer Using Cisplatin, Fluorouracil, and Docetaxel Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Laryngeal squamous cell carcinoma
    • Squamous cell carcinoma of the hypopharynx
    Investigated Drugs:
    • Cisplatin
    • Docetaxel
    • Fluorouracil
    France

  • Study on Trastuzumab and Pertuzumab for Patients with HER2-Positive Breast Cancer Using a Response-Adapted Strategy

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Docetaxel
    • Letrozole
    France Germany Italy Portugal Spain

  • Study on Enfortumab Vedotin and Pembrolizumab for Patients with Advanced Urothelial Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma urethra
    • Transitional cell cancer of the renal pelvis and ureter
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Enfortumab Vedotin
    • Pembrolizumab
    France

  • Study of Pembrolizumab and Axitinib Combination Versus Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic renal cell carcinoma
    Investigated Drugs:
    • Axitinib
    • Pembrolizumab
    • Sunitinib
    Czechia France Germany Hungary Ireland Poland +1

  • Study Comparing Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil to Standard Treatment for Patients with Advanced Anal Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Anal squamous cell carcinoma
    Investigated Drugs:
    • Mitomycin
    • Capecitabine
    • Cisplatin
    France

  • Study of Pembrolizumab, Favezelimab, and Lenvatinib for Patients with Renal Cell Carcinoma

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Vibostolimab
    • Belzutifan
    • Favezelimab
    France Hungary The Netherlands Poland Spain

  • Study of Pembrolizumab in Patients with Esophageal Cancer Undergoing Chemoradiotherapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Oesophageal carcinoma
    Investigated Drugs:
    • Calcium Folinate
    • Cisplatin
    • Fluorouracil
    Belgium Czechia Denmark Estonia France Germany +4

  • Study on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Alpelisib
    • Fulvestrant
    • Goserelin
    France

  • Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer recurrent
    Investigated Drugs:
    • Gallium (68Ga) Gozetotide
    • Piflufolastat (18F)
    • Darolutamide
    Austria Belgium Czechia Denmark Finland France +8
Previous Page
1 … 15 16 17 18
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!